Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients.
about
Thymidine kinase 1 upregulation is an early event in breast tumor formationProteomics of mouse BRCA1-deficient mammary tumors identifies DNA repair proteins with potential diagnostic and prognostic value in human breast cancerBiological markers of invasive breast cancerPrognostic value of different cut-off levels of Ki-67 in breast cancer: a systematic review and meta-analysis of 64,196 patients.High Ki-67 Immunohistochemical Reactivity Correlates With Poor Prognosis in Bladder Carcinoma: A Comprehensive Meta-Analysis with 13,053 Patients InvolvedRespective prognostic value of genomic grade and histological proliferation markers in early stage (pN0) breast carcinomaA Randomized Phase II Neoadjuvant Study of Cisplatin, Paclitaxel With or Without Everolimus in Patients with Stage II/III Triple-Negative Breast Cancer (TNBC): Responses and Long-term Outcome Correlated with Increased Frequency of DNA Damage ResponsOverview of data-synthesis in systematic reviews of studies on outcome prediction models.Small-molecule targeting of proliferating cell nuclear antigen chromatin association inhibits tumor cell growth.Proliferating cell nuclear antigen is a novel inhibitory ligand for the natural cytotoxicity receptor NKp44.Limitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.ImmunoRatio: a publicly available web application for quantitative image analysis of estrogen receptor (ER), progesterone receptor (PR), and Ki-67Evaluation of the bioconjugation efficiency of different quantum dots as probes for immunostaining tumor-marker proteins.A novel model for Ki67 assessment in breast cancer.Development and evaluation of a virtual microscopy application for automated assessment of Ki-67 expression in breast cancer.Contribution of nestin positive esophageal squamous cancer cells on malignant proliferation, apoptosis, and poor prognosisEvaluating the response of neoadjuvant chemotherapy for treatment of breast cancer: are tumor biomarkers and dynamic contrast enhanced MR images useful predictive tools?Ki67 expression in invasive breast cancer: the use of tissue microarrays compared with whole tissue sections.Analytical validation of a standardized scoring protocol for Ki67: phase 3 of an international multicenter collaboration.Ki67, chemotherapy response, and prognosis in breast cancer patients receiving neoadjuvant treatment.Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640Initiation and termination of DNA replication during S phase in relation to cyclins D1, E and A, p21WAF1, Cdt1 and the p12 subunit of DNA polymerase δ revealed in individual cells by cytometryPhytohemagglutinin-induced mitotic index in blood lymphocytes: a potential biomarker for breast cancer risk.Lobular breast cancers lack the inverse relationship between ER/PR status and cell growth rate characteristic of ductal cancers in two independent patient cohorts: implications for tumor biology and adjuvant therapyLong-term prognostic performance of Ki67 rate in early stage, pT1-pT2, pN0, invasive breast carcinoma.Proliferative activity in human breast cancer: Ki-67 automated evaluation and the influence of different Ki-67 equivalent antibodiesEnhanced expression of cyclins and cyclin-dependent kinases in aniline-induced cell proliferation in rat spleen.Genomic instability: a stronger prognostic marker than proliferation for early stage luminal breast carcinomas.Clinical and histopathological factors associated with Ki-67 expression in breast cancer patients.Estrogen receptor-negative breast ductal carcinoma: clinicopathological features and MIB-1 (Ki-67) proliferative index associationPrediction of outcome of early ER+ breast cancer is improved using a biomarker panel, which includes Ki-67 and p53.Development of radiotracers for oncology--the interface with pharmacologyEstablishment and characterization of a new cell line of canine inflammatory mammary cancer: IPC-366Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working groupAn interobserver reproducibility analysis of Ki67 visual assessment in breast cancer.Preoperative Prediction of Ki-67 Labeling Index By Three-dimensional CT Image Parameters for Differential Diagnosis Of Ground-Glass Opacity (GGO).Comparison of visual and automated assessment of Ki-67 proliferative activity and their impact on outcome in primary operable invasive ductal breast cancer.Breast cancer biological subtypes and protein expression predict for the preferential distant metastasis sites: a nationwide cohort study.Protein expression, survival and docetaxel benefit in node-positive breast cancer treated with adjuvant chemotherapy in the FNCLCC-PACS 01 randomized trialKi-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review
P2860
Q21285027-D8E0859C-E2B5-438C-A96A-B39EA5467C7EQ24632628-DCD61E83-5D80-4939-9834-B7790C287F1CQ26781177-5B5BDEB0-D866-4275-BF15-F1E84D5D2D34Q27853207-22E05E7D-1A36-4CA0-880A-4373994F19FAQ28070330-B8F518C4-36BC-425F-A609-588FB1AFC8B5Q28730529-EA264CF2-E40E-41B3-B289-E341AB159FC8Q30253017-9F96B83A-99CB-4ED8-816F-9FD0439D8D74Q30599542-BA14A857-9887-4C99-9D45-768CDDB06D6AQ31049735-24DBA0B2-0212-4B05-9A40-C9C394DDFB11Q33292532-78C29E18-80F9-486E-815F-E07C72C9A44FQ33591751-CD513AB9-FB67-4406-AC5C-4B4402341747Q33642280-5CC2CAE7-4843-401D-9121-265ACBB7787AQ33662783-3C5577FF-FD34-4A76-B26E-2EE438FD0FFFQ33801255-F220EEB3-43CD-48CA-BD5A-1EA9727DFB70Q33801758-8035AB48-5B82-469D-BBBC-31B43BB730A7Q33806924-5FEF5779-64E3-48B7-8932-F4DC1A86A3E0Q33814616-762934EA-3881-422C-A2C0-0FCC5230CCCDQ33843751-66D10F26-32B3-45A8-8302-B87B7AF8F624Q33915010-1922B3E0-9A60-464E-BF9F-3DDC01E0DC37Q34074094-F3719ED8-19AF-44DD-8784-310A75C29DFBQ34197851-433FA6AD-431A-457D-AAE9-A432C475575CQ34480026-C0AAA124-78A8-4509-B38C-8A222743980CQ34480468-039FDE97-E2DC-4E01-97B9-89A54B8A317DQ34537257-213723A1-F647-4230-83EE-B6560FAE6723Q34633934-96FBF293-0C30-43DF-8318-0EC12950D13AQ34775344-71BE9628-6DEF-4B4A-84BE-812ED43CFAF8Q34791571-67BA0B38-3DF8-47C9-A869-FDAB1A8B7C91Q35021646-4CA12EC1-8A88-4AA4-ADB2-A1C36B1AB1B4Q35042063-06E98FDD-CC93-4E32-8155-03D04C4C280AQ35106790-1FBB3DFD-124D-48F1-91E8-B2740F4F06F3Q35125648-03C7A634-EC96-4899-95CC-C8EC73C9CB60Q35195500-3CF24B14-DED5-42F3-B138-2D25FA030E51Q35217289-14C2A201-CCD1-441D-AA01-2B6C759A1E05Q35552069-1E4B742B-DF5C-4716-941B-B131A1C528E0Q35560945-33598A3C-AB05-4D49-9D4C-15684205EB44Q35659702-9F4938F1-E8A1-479A-992F-5E2B21B5D197Q35681966-53688AA5-3F17-41C8-A466-3A7A57A23070Q35683537-E3BBD455-8FEC-4DF7-9E14-ED83D3352E01Q35889568-56574833-3A66-4E54-8641-D2EDFBB8BDAEQ35904441-F86D65D8-9C4D-42FD-8268-53BAB9FFF045
P2860
Proliferation markers and survival in early breast cancer: a systematic review and meta-analysis of 85 studies in 32,825 patients.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Proliferation markers and surv ...... 85 studies in 32,825 patients.
@en
Proliferation markers and surv ...... 85 studies in 32,825 patients.
@nl
type
label
Proliferation markers and surv ...... 85 studies in 32,825 patients.
@en
Proliferation markers and surv ...... 85 studies in 32,825 patients.
@nl
prefLabel
Proliferation markers and surv ...... 85 studies in 32,825 patients.
@en
Proliferation markers and surv ...... 85 studies in 32,825 patients.
@nl
P50
P1433
P1476
Proliferation markers and surv ...... 85 studies in 32,825 patients.
@en
P2093
R Stuart-Harris
P304
P356
10.1016/J.BREAST.2008.02.002
P577
2008-05-02T00:00:00Z